SCHEMBL3148517

SCHEMBL3148517

COc1ccc(OC2CCCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ CA12 O43570 1/20 0.48
▸ CA1 P00915 1/20 0.48
▸ CA2 P00918 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ CA9 Q16790 1/20 0.48
▸ CA14 Q9ULX7 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ PARP10 Q53GL7 1/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ FFAR1 O14842 1/20 0.45
▸ PDGFRB P09619 1/20 0.45
▸ PDGFRA P16234 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1071370 0.98 MAPT (0.53) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL16838744 0.89 SMN1; SMN2 (0.56) MAPTSMN1; SMN2CA12CA1CA2
SCHEMBL2242868 0.89 PARP10 (0.55) PARP10FFAR1HPGDALDH1A1TSHR
SCHEMBL257928 0.83 EGFR (0.48) KDM4EPARP10MEN1KMT2AFFAR1
SCHEMBL18210781 0.83 EGFR (0.48) KDM4EPARP10MEN1KMT2AFFAR1
SCHEMBL21118540 0.81 FFAR1 (0.40) MAPTSMN1; SMN2MEN1KMT2AFFAR1
SCHEMBL12302802 0.80 SLC6A2 (0.61) MAPTSMN1; SMN2RAB9APDGFRBPDGFRA
SCHEMBL8171032 0.80 EGFR (0.49) KDM4EPARP10MEN1KMT2AFFAR1
SCHEMBL623629 0.80 PARP10 (0.53) PARP10HPGDALDH1A1TSHRTDP1
SCHEMBL942628 0.79 HRH1 (0.66) MAPTSMN1; SMN2MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873288-B2 Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-01-16 — — US disclosed
US-20210155601-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-05-27 — — US disclosed
US-10858338-B2 Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-12-08 — — US disclosed
US-20190077785-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-03-14 — — US disclosed
WO-2017160861-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-09-21 — — WO disclosed
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 — — EP disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 — — US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 — — US disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 — — EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 — — WO disclosed
EP-1033621-B1 Silver halide color photosensitive material and color image forming method using the same FUJIFILM CORP (JP) 2008-08-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C MAPT 1382/4885SMN1; SMN2 728/4885CA12 4385/4885
US-11873288-B2 Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) FAAH, FAAH2, EPHX2 MAPT 4665/4885SMN1; SMN2 4514/4885CA12 1827/4885
US-20210155601-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) FAAH, FAAH2, EPHX2 MAPT 4665/4885SMN1; SMN2 4514/4885CA12 1827/4885
US-10858338-B2 Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH) FAAH, FAAH2, EPHX2 MAPT 4665/4885SMN1; SMN2 4514/4885CA12 1827/4885
US-20190077785-A1 INHIBITORS FOR SOLUBLE EPOXIDE HYDROLASE (SEH) AND FATTY ACID AMIDE HYDROLASE (FAAH) FAAH, FAAH2, EPHX2 MAPT 4665/4885SMN1; SMN2 4514/4885CA12 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback